BioSpace News Archive

Over 120 million Americans have tried CBD, with the numbers increasing on a daily basis, and two-thirds of US states, and 22 countries, have legalized marijuana for medical purposes.

LumaCyte, an advanced research and bioanalytics instrumentation company headquartered in Charlottesville, VA, announces the third doubling of their manufacturing and laboratory space.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced that on September 11, 2019, the Company held a meeting with investigators in Shanghai to launch the Phase II clinical trial for AlloJoin®, an “off-the-shelf” allogenic human adipose-derived mesenchymal progenitor cell therapy product targeting Knee Osteoarthritis (KOA).

Hollins Communications Research Institute (HCRI), a national center for stuttering research and therapy innovation, just completed another research initiative in collaboration with the National Institutes of Health (NIH).

Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in inflammatory and dermatological disease drug development.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled, “Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.”

Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Conference on Saturday, September 14 at 4:00 p.m. ET.

Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research data from cannabinoid tests on live cancer biopsies at the 2nd International Cannabinoid Derived Pharmaceuticals Summit, to be held in Boston, MA

Massage Envy, the nation’s #1 provider of massage and skin care services, announced a breakthrough new acne series to be rolled out nationally by early 2020.

Beacon of Hope CRO (bohcro.com), which helps companies provide safe, ethical and legal patient access to their investigational treatments outside of traditional clinical trials, is launching this month at the ALS Association Florida Chapter Hope and Help Symposium, on September 14th, in Orlando, FL, where it is an exhibitor.